Ticagrelor 60mg

DRUG10 trials

Conditions

Acute Coronary SyndromeAcute Myocardial InfarctionAntiplatelet TherapyAortic Valve StenosisCoronary Artery DiseaseCoronary Stent ImplantationNSTEMIPercutaneous Coronary Intervention

Phase 1

De-escalation of Ticagrelor in Post PPCI

NCT05831462

Assiut UniversityTicagrelor

Start: 2023-06-01End: 2024-05-01Target: 400Updated: 2023-04-26

Phase 3

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

NCT04718025

Collegium Medicum w BydgoszczyNSTEMI, STEMI, Unstable Angina

Start: 2022-02-07End: 2024-06-30Target: 4500Updated: 2023-04-21

Phase 4

A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

TerminatedNCT03224923

Ottawa Heart Institute Research CorporationAntiplatelet Therapy, Percutaneous Coronary Intervention, Stable Coronary Syndrome +1

Start: 2017-08-18End: 2018-09-30Updated: 2019-07-19

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

NCT04255602

Shanghai Tong Ren HospitalAcute Coronary Syndrome, Coronary Stent Implantation

Start: 2020-02-19End: 2024-12-31Target: 2120Updated: 2023-12-07

Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation

CompletedNCT04331145

Andres Iñiguez RomoSymptomatic Aortic Stenosis

Start: 2020-06-23End: 2022-02-28Updated: 2022-03-02

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

CompletedNCT04483583

University of FloridaCoronary Artery Disease

Start: 2020-12-08End: 2025-01-07Updated: 2025-07-31

Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

NCT04734353

Gyeongsang National University HospitalCoronary Artery Disease

Start: 2020-01-15End: 2022-06-15Target: 492Updated: 2021-02-02

Optimal Dosage of Ticagrelor in Korean Patients With AMI

NCT05210595

Dong-A UniversityAcute Myocardial Infarction, Ticagrelor

Start: 2022-01-01End: 2023-12-31Target: 120Updated: 2022-01-27

Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

NCT05283356

Fundacin Biomedica Galicia SurAortic Valve Stenosis, Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation (TAVI) +1

Start: 2022-01-21End: 2025-06-30Target: 1206Updated: 2022-03-31

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

RecruitingNCT06228456

University of FloridaCoronary Artery Disease

Start: 2024-04-01End: 2027-04-30Target: 50Updated: 2026-02-05

Related Papers

Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation.

2025-11-01

P2Y<sub>12</sub> Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study.

2024-04-078 citations

A randomized non-inferiority study of low-dose and standard-dose ticagrelor after intervention for acute coronary syndrome: study protocol for the TIGER STUDY.

2022-03-05

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study

Cardiology Journal2021-06-0713 citations